Table 2.
Demographic Characteristics, Side Effects, and Drug Compliance in Two Groups Divided by a Cutoff Point of 15 of the Posttreatment Value of the Urea Breath Test After Failed Triple Therapy
| Variables | Posttreatment Value ≤15 (n =36) | Posttreatment Value >15 (n =34) | P Value |
|---|---|---|---|
| Mean age, y | 44.4 | 43.5 | NS |
| Female, % (n) | 50 (18) | 50 (17) | NS |
| Endoscopic findings, (n) | |||
| DU:NUD | 25:11 | 24:10 | NS |
| Compliance with triple therapy, % (n) | |||
| Good (7-day) | 55.6 (20) | 55.9 (19) | NS |
| Modest (>5 &<7 days) | 33.3 (12) | 32.3 (11) | NS |
| Poor (<5 days) & dropout | 11.1 (4) | 11.8 (4) | NS |
| Side effects, n | |||
| Nausea/vomiting | 5 | 5 | NS |
| Constipation | 5 | 6 | NS |
| Diarrhea | 6 | 6 | NS |
| Metallic taste | 6 | 9 | NS |
| H. pylori isolates,* % (n) | |||
| Metronidazole Resistance (MR) | 45 (9) | 42.4 (14) | NS |
| Clarithromycin Resistance (CR) | 20 (4) | 93.9 (31) | <.05 |
| Both MR & CR | 10 (2) | 39.3 (13) | <.05 |
*
Fifty-three H. pylori isolates (20 from patients with a posttreatment value less than 15/ml, 33 from patients with a value more than 15/ml) collected before rescue therapy.
DU, duodenal ulcer; NUD, nonulcer gastritis.